EVALUATION OF HER– 2/neu STATUS IN CARCINOMA BREAST SPECIMENS USING IMMUNO–HISTOCHEMISTRY (IHC) & FLUORESCENCE IN SITU HYBRIDISATION (FISH) ASSAY

Dr V.Lakshmi; Dr V.Jyothi; Dr. Vasundhara; Dr Tamil Arasi

Volume : VII, Issue : X, October - 2017

EVALUATION OF HER– 2/neu STATUS IN CARCINOMA BREAST SPECIMENS USING IMMUNO–HISTOCHEMISTRY (IHC) & FLUORESCENCE IN SITU HYBRIDISATION (FISH) ASSAY

Dr V. Lakshmi, Dr V. Jyothi, Dr. Vasundhara, Dr Tamil Arasi

Abstract :

Breast cancer is the second most common cancer in the world and by far the most frequent cancer among women. Among the various prognostic and predictive factors of east cancer, the most widely studied biomarker is the human epidermal growth factor receptor 2 (HER–2) gene, also referred to as ERBB2/erbb2 or HER–2/neu by IHC & FISH. AIMS AND OBJECTIVES: To evaluate the association between HER– 2/neu status and Comparison of Fluorescence In Situ Hyidization an Immunohistochemistry. MATERIALS & METHODS The present study was conducted at the Department of Pathology, Kurnool Medical College, Kurnool. It is a prospective study done between june 2014 to june 2016.the study material consists of 60 cases 0f mastectomy specimensof east carcinoma which were selected for HER–2/neu status by IHC & FISH.RESULTS: Immunohistochemistry for HER2/neu as per American Society of Clinical Oncology ⁄ College of American Pathologists (ASCO ⁄ CAP) guidelines revealed that 18(30%) cases were HER–2/neu positive, 9(15%) were equivocal and 33 cases (55%) were negative. CONCLUSION In conclusion, in the present study both IHC and FISH were employed for determination of HER–2/neu status in invasive east carcinoma. With most authorities agreeing upon FISH to be more reliable than IHC for determining the HER–2 status